First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for their...

Since stepping into his new role in March as president of Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG , James "Jay" Bradner has been busy making plans to experiment with open...

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high...

OXFORD - Europe will end up with about 100 companies and 60 of those will be British. That was the bold prediction of Chris Evans, one of Britain's most outspoken biotech entrepreneurs and founder of Merlin...

OXFORD - Copenhagen looks poised to become the focus of European IPO activity in 1998. The post-IPO track record of NeuroSearch A/S in the past 15 months - which has seen the value of NEUS rise threefold...